▲ S&P 500 +---% | ▲ Stock Advisor +---% Join The Motley Fool

Accessibility Log In Help

Daily Stock Gainers Daily Stock Losers Most Active Stocks

Daily Stock Gainers Daily Stock Losers Most Active Stocks

Todd Campbell

tmfebcapital

@ebcapital

Todd has been helping buy side portfolio managers as an independent researcher for over a decade. In 2003, Todd founded E.B. Capital Markets, LLC, a research firm providing action oriented ideas to professional investors. Todd has provided insight to a variety of publications, including SmartMoney, Barron's, and CNN/fn.

Recent Articles by Todd Campbell

Sep 26, 2014 by Todd Campbell

The 5 Best Biotech Stocks in 2014...so far

Here's why these five companies are biotech's top performers this year.

Sep 25, 2014 by Todd Campbell

Not Even a Weight Loss Drug Could Stop Orexigen Therapeutics, Inc. From Dropping 20% in 2014

Despite winning FDA approval for the weight loss drug Contrave, Orexigen's shares have tumbled this year.

Sep 25, 2014 by Todd Campbell

The Next Blue Chip Stocks: WellPoint Inc

WellPoint's growth from healthcare reform and ageing seniors positions it perfectly to become one of America's most important companies.

Sep 24, 2014 by Todd Campbell

The Next Blue Chip Stocks: Gilead Sciences, Inc.

Gilead Sciences robust HIV drug franchise and blockbuster hepatitis C drugs position it for coveted blue chip status.

Sep 23, 2014 by Todd Campbell

Is Walgreen Company a Value Stock Following Its 20% Tumble?

Walgreen's decision not to do a tax inversion has sent shares stumbling, but that may be creating value for investors looking for a bargain.

Sep 23, 2014 by Todd Campbell

Why Geron Corporation Stock Is Down a Shocking 52% in 2014

The FDA's clinical hold on imetelstat has rocked Geron's shares this year.

Sep 22, 2014 by Todd Campbell

Is There Hope for Rite Aid Corporation Stock After It's Horrendous Quarter?

Rite Aid is stumbling due to falling generic drug margins, yet shares are clinging to a year-to-date gain.

Sep 18, 2014 by Todd Campbell

Gilead Sciences, inc. Stock's Incoming Game Changer

Gilead's Sovaldi sales could reach $10 billion this year, but sales could head even higher next year if the FDA approves its Sovaldi and ledipasvir combination drug.

Sep 18, 2014 by Todd Campbell

3 Best Stocks for Investing in Biotech

Gilead Sciences, Celgene Corp, and BioMarin are three biotech industry companies that are revolutionizing how doctors treat patients.

Sep 17, 2014 by Todd Campbell

Why Amgen Inc.'s Stock Is up 23% in 2014

Amgen is rallying on hope surrounding a new class of PCSK9 inhibitors designed to reduce bad cholesterol.

Sep 17, 2014 by Todd Campbell

Why CVS Health Corporation Is Up 14.8% in 2014

CVS Health's shift toward primary care services is boosting both sales and share prices.

Sep 17, 2014 by Todd Campbell

Rite Aid Corporation Stock Earnings: 3 Key Things to Watch

Here are three important questions Rite Aid needs to address during its earnings conference call on September 18th.

Sep 15, 2014 by Todd Campbell

Why Is Gilead Sciences, Inc. Stock Offering This Drug for Cheap?

Gilead Sciences will collect royalties on generic Sovaldi beginning as early as next year, even as it launches its next generation hepatitis C drug here in the United States.

Sep 14, 2014 by Todd Campbell

Why Cloud Hackers Could Come for Your Health Data Next

Hackers are exploiting the heartbleed bug as part of their increased attacks to steal private healthcare information.

Sep 13, 2014 by Todd Campbell

Is Medical Marijuana Destined to Become a Top Schizophrenia Treatment?

Despite worries over reefer madness, research by GW Pharmaceuticals might show that medical marijuana may reduce schizophrenia symptoms.

Sep 12, 2014 by Todd Campbell

Surprising New Competitor: Should Arena Pharmaceuticals, Inc. and Orexigen Therapeutics, Inc. Be Afraid?

A new weight loss pill from Orexigen will face stiff competition from Arena's Belviq and may soon have to compete against Novo Nordisk's Saxenda.

Sep 12, 2014 by Todd Campbell

Apple Watch's Huge Future Opportunity

Apple Watch aims to provide consumers with a brand new way of tracking and monitoring health.

Sep 12, 2014 by Todd Campbell

Why ISIS Pharmaceuticals Inc. Stock Is Flat in 2014

ISIS Pharmaceuticals shares have rebounded since spring, but still remain unchanged this year as investors digest a big stock move last year and wait for further proof that antisense RNA technology has blockbuster potential.

Sep 12, 2014 by Todd Campbell

Why Biogen Idec Inc's Stock is Up 17% in 2014

Biogen's Tecfidera, an oral multiple sclerosis treatment, is helping lift its stock this year, but Tecfidera isn't the only reason Biogen's shares may continue to climb.

Sep 11, 2014 by Todd Campbell

Why Gilead Sciences Stock Is Up 40% in 2014

Gilead's shares have surged this year, but that may not mean the shares are ready to drop.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.

View Premium Services